A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer
This study is looking at the best way to treat intermediate-risk prostate cancer using high-dose radiation therapy. Researchers want to find out if adding short-term hormone-blocking therapy to radiation works better than radiation alone in fighting the cancer.
You might be able to join if you have been recently diagnosed with intermediate-risk prostate cancer that has not spread. People with certain previous treatments or more advanced cancers cannot take part.
Participants will receive high-dose radiation treatment to target the cancer cells. Depending on which group you are placed in, you may also receive hormone-lowering medications.
This study took place at multiple medical centers across the United States, including locations in Alabama, Alaska, and Arizona. The study has now been completed.
- 1Tests radiation therapy with or without hormone-blocking medications
- 2Focuses on intermediate-risk prostate cancer
- 3This study is now completed
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.